As coronavirus disrupts MNC operations in China, companies look to digital solutions
Biopharma will need to turn to digital solutions in China in the face of the coronavirus crisis
The coronavirus outbreak in China has triggered a stark call to action across the international biopharma community to treat, diagnose and prevent the spread of the virus, but it has also revealed some cracks in China's infrastructure that have upended clinical and commercial operations in the region. The resulting crisis may ultimately push MNCs, Chinese biopharmas and regulators to accelerate adoption of digital trial monitoring and marketing tools, and decentralization of trial sites, in order to avoid similar issues in the future.
For MNCs and Chinese biopharmas, one of the biggest operational impacts of the crisis will be on clinical trials. Healthcare resources are being diverted to address the epidemic and patient visits to hospitals are restricted to prevent the spread of disease. ...